Also trades as: LADX (OTC) · $vol 0M
CYTR OTC
LadRx Corporation
1W: +1.9%
1M: +8.6%
3M: -23.2%
1Y: -84.2%
3Y: -78.2%
5Y: -97.2%
$0.09
Last traded 2022-10-05 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.05-0.86
Volume942
Avg Volume57,006
Beta2.10
Dividend$10.46
Analyst Ratings
Company Info
CEOSteven Kriegsman
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date1986-11-10
Websitecytrx.com
11726 San Vicente Blvd Ste 650
Los Angeles, CA 90049
US
Los Angeles, CA 90049
US
13108265648
About LadRx Corporation
LadRx Corporation is a biopharmaceutical firm focused on identifying and advancing treatments for cancer patients. Its primary drug candidate, aldoxorubicin, which is a modified variant of the anti-cancer medication doxorubicin, is currently in late-stage clinical assessment. Additionally, the company possesses a pipeline of preclinical therapeutics, including linker activated drug releases (LADRs) numbered 7, 8, 9, and 10, all designed to target cancerous cells. Founded in 1985, this Los Angeles, California-based company adopted its current name, LadRx Corporation, in September 2022, having previously operated as CytRx Corporation.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Claiborne Cary J | 0 | — | 2022-07-27 | |
| Snowdy Stephen | 0 | — | 2022-01-10 | |
| Snowdy Stephen | A-Award | 300,000 | $0.64 | 2022-01-10 |
| Simpson Jennifer K. | A-Award | 50,000 | $0.45 | 2021-12-15 |
| Simpson Jennifer K. | A-Award | 25,000 | — | 2021-12-15 |